Comparative Pharmacology
Head-to-head clinical analysis: CABERGOLINE versus MIRAPEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CABERGOLINE versus MIRAPEX.
CABERGOLINE vs MIRAPEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cabergoline is a long-acting dopamine D2 receptor agonist that inhibits prolactin secretion by the anterior pituitary gland.
Dopamine receptor agonist (D3 > D2 > D4) with activity at α2-adrenergic and 5-HT1A receptors; increases dopamine receptor activation in striatum.
0.25 mg orally twice weekly, up to 1 mg twice weekly; for hyperprolactinemia, initial 0.25 mg twice weekly, titrate by 0.25 mg every 4 weeks based on prolactin levels.
Initial: 0.375 mg orally once daily; titrate gradually based on efficacy and tolerability. Usual effective dose: 1.5-4.5 mg daily in 3 divided doses. Maximum dose: 4.5 mg/day.
None Documented
None Documented
Terminal elimination half-life is 63-68 hours in healthy subjects, allowing for once- or twice-weekly dosing. In hepatic impairment, half-life may be prolonged.
Clinical Note
moderateCabergoline + Digoxin
"Cabergoline may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCabergoline + Digitoxin
"Cabergoline may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCabergoline + Deslanoside
"Cabergoline may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCabergoline + Acetyldigitoxin
"Cabergoline may decrease the cardiotoxic activities of Acetyldigitoxin."
The terminal elimination half-life is 8–12 hours in healthy adults, allowing for three-times-daily dosing. In elderly patients, half-life may be prolonged to 12–14 hours due to age-related decline in renal function.
Approximately 60-70% of the dose is excreted in feces (primarily as unchanged drug and metabolites), with about 20-30% excreted renally (mostly as metabolites).
Renal elimination accounts for approximately 90% of total clearance, with about 80% recovered as unchanged parent drug in urine. Biliary/fecal excretion is minimal (<10%).
Category A/B
Category C
Dopamine Agonist
Dopamine Agonist